News headlines about Psychemedics Corporation (NASDAQ:PMD) have trended somewhat negative on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Psychemedics Corporation earned a media sentiment score of -0.08 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.2276360893488 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Psychemedics Corporation (PMD) traded up 2.00% during mid-day trading on Wednesday, hitting $19.88. The stock had a trading volume of 6,109 shares. Psychemedics Corporation has a 12 month low of $13.81 and a 12 month high of $27.99. The company has a market cap of $109.16 million, a price-to-earnings ratio of 14.67 and a beta of 1.02. The firm’s 50-day moving average is $21.76 and its 200 day moving average is $21.60.
Psychemedics Corporation (NASDAQ:PMD) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported $0.16 earnings per share (EPS) for the quarter. The company had revenue of $9.68 million during the quarter. Psychemedics Corporation had a return on equity of 47.94% and a net margin of 17.59%. Equities analysts anticipate that Psychemedics Corporation will post $0.93 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 24th. Investors of record on Monday, August 14th were paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 3.08%. The ex-dividend date of this dividend was Thursday, August 10th. Psychemedics Corporation’s dividend payout ratio is 44.44%.
COPYRIGHT VIOLATION NOTICE: “Psychemedics Corporation (PMD) Given Media Impact Rating of -0.08” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/09/13/psychemedics-corporation-pmd-given-media-impact-rating-of-0-08.html.
In related news, VP Michael I. Schaffer sold 4,400 shares of Psychemedics Corporation stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $20.37, for a total transaction of $89,628.00. Following the completion of the sale, the vice president now owns 41,273 shares of the company’s stock, valued at $840,731.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael I. Schaffer sold 7,548 shares of Psychemedics Corporation stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $20.41, for a total value of $154,054.68. Following the sale, the vice president now directly owns 41,273 shares of the company’s stock, valued at approximately $842,381.93. The disclosure for this sale can be found here. Insiders have sold 12,929 shares of company stock valued at $264,441 in the last three months. 8.60% of the stock is owned by corporate insiders.
Psychemedics Corporation Company Profile
Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment.
Receive News & Ratings for Psychemedics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.